Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

Aim: The effect on body composition of liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue, as monotherapy or added to metformin was examined in patients with type 2 diabetes (T2D).

[1]  B. Zinman,et al.  Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230)) , 2010 .

[2]  A. Vaag,et al.  Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial , 2009, Diabetologia.

[3]  J. Rosenstock,et al.  Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) , 2009, The Lancet.

[4]  D. Drucker,et al.  Incretin-based therapies for type 2 diabetes mellitus , 2009, Nature Reviews Endocrinology.

[5]  B. Zinman,et al.  Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) , 2009, Diabetes Care.

[6]  S. Colagiuri,et al.  Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[7]  B. Bode,et al.  Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial , 2009, The Lancet.

[8]  D. Matthews,et al.  Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes , 2008, Diabetes Care.

[9]  B. Zinman,et al.  Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus ( LEAD-4 Met + TZD ) , 2009 .

[10]  N. Freemantle,et al.  How strong is the association between abdominal obesity and the incidence of type 2 diabetes? , 2008, International journal of clinical practice.

[11]  R. Ross,et al.  Is the reduction of lower-body subcutaneous adipose tissue associated with elevations in risk factors for diabetes and cardiovascular disease? , 2008, Diabetologia.

[12]  J. Divers,et al.  Disruptions in energy balance: Does nature overcome nurture? , 2008, Physiology & Behavior.

[13]  S. Amiel,et al.  Hypoglycaemia in Type 2 diabetes , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[14]  G. Frühbeck.  Overview of adipose tissue and its role in obesity and metabolic disorders. , 2008, Methods in molecular biology.

[15]  D. Klonoff,et al.  Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. , 2008, Current medical research and opinion.

[16]  D. Drucker,et al.  Incretin Receptors for Glucagon-Like Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Are Essential for the Sustained Metabolic Actions of Vildagliptin in Mice , 2007, Diabetes.

[17]  D. Russell-Jones,et al.  Insulin‐associated weight gain in diabetes – causes, effects and coping strategies , 2007, Diabetes, obesity & metabolism.

[18]  J. Pogue,et al.  Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. , 2007, European heart journal.

[19]  L. B. Knudsen,et al.  Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not , 2007, Diabetes.

[20]  N. Greig,et al.  In vivo biological activity of exendin (1–30) , 2005, Endocrine.

[21]  K. Hermansen,et al.  Bodyweight Changes Associated with Antihyperglycaemic Agents in Type 2 Diabetes Mellitus , 2007, Drug safety.

[22]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[23]  N. Abumrad,et al.  Is all fat the same? The role of fat in the pathogenesis of the metabolic syndrome and type 2 diabetes mellitus. , 2006, Surgery.

[24]  A. Young,et al.  Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures , 2006, International Journal of Obesity.

[25]  D. Mukhopadhyay,et al.  Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. , 2006, Diabetes care.

[26]  F. Anania,et al.  Exendin‐4, a glucagon‐like protein‐1 (GLP‐1) receptor agonist, reverses hepatic steatosis in ob/ob mice , 2006, Hepatology.

[27]  Sukru Mehmet Erturk,et al.  Computed Tomography Features of Nonalcoholic Steatohepatitis With Histopathologic Correlation , 2006, Journal of computer assisted tomography.

[28]  Jerry D Meece,et al.  Dispelling Myths and Removing Barriers About Insulin in Type 2 Diabetes , 2006, The Diabetes educator.

[29]  D. Akbar,et al.  Non-alcoholic fatty liver disease and metabolic syndrome: what we know and what we don't know. , 2006, Medical science monitor : international medical journal of experimental and clinical research.

[30]  H. Lebovitz,et al.  Point: visceral adiposity is causally related to insulin resistance. , 2005, Diabetes care.

[31]  J. R. Rodríguez-Moctezuma,et al.  Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes , 2005, Diabetes, obesity & metabolism.

[32]  G. Bray,et al.  Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. , 2005, Metabolism: clinical and experimental.

[33]  R. Ross,et al.  Interindividual variation in abdominal subcutaneous and visceral adipose tissue: influence of measurement site. , 2004, Journal of applied physiology.

[34]  A. Astrup,et al.  The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. , 2004, Diabetes care.

[35]  D. Doddrell,et al.  Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. , 2002, Obesity research.

[36]  S. Heymsfield,et al.  Total-body skeletal muscle mass: estimation by a new dual-energy X-ray absorptiometry method. , 2002, The American journal of clinical nutrition.

[37]  J. Holst,et al.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study , 2002, The Lancet.

[38]  M. Zdravkovic,et al.  The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men , 2002, Diabetologia.

[39]  A. Astrup,et al.  A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. , 2001, The Journal of clinical endocrinology and metabolism.

[40]  I. Gabriely,et al.  The role of fat depletion in the biological benefits of caloric restriction. , 2001, The Journal of nutrition.

[41]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[42]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[43]  P A Cleary,et al.  Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. , 1998, JAMA.

[44]  A. Astrup,et al.  Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. , 1998, The Journal of clinical investigation.